DandruffscalpNCT07459023
Changes in Scalp Condition After Using a Moisturizer: a Prospective Clinical Trial Using Artificial Intelligence
A study testing Ducray Kertyol P.S.O. Concentrate Cream, Ducray Laboratory, France in people with Dandruff and Seborrhoeic Dermatitis of the Scalp, run by Seoul National University Bundang Hospital at 1 site in South Korea.
Trial summary
The goal of this clinical trial is to evaluate whether a scalp moisturizer containing celastrol and Cichorium intybus root extract can improve scalp condition in adults aged 19 years or older who require scalp moisturization due to dryness, scaling, erythema, or dandruff. Read more about this study
- Who is it for?
- Ages 19 years and olderHealthy volunteers can take part
- Conditions the study is for
- Dandruff, Seborrhoeic Dermatitis of the Scalp
- What is being tested?
- Ducray Kertyol P.S.O. Concentrate Cream, Ducray Laboratory, France
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 23 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Jul 2025to 31 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥19 years
- Presence of scalp erythema, dryness, scaling, or dandruff requiring scalp moisturization
Who cannot join
- Active infectious scalp dermatoses
- Use of topical or systemic therapies affecting scalp status within 4 weeks prior to enrollment or during the study period
- Inability to comply with the study protocol
Trial locations and contacts
1 site in 1 country.
South Korea1 site
Seoul National University Bundang Hospital
Seongnam-si, Kyeonggi
About this study
Official title: Changes in Scalp Condition After Using a Moisturizer Containing Celastrol and Cichorium Intybus Root Extract: a Prospective Clinical Trial Using Artificial Intelligence
The goal of this clinical trial is to evaluate whether a scalp moisturizer containing celastrol and Cichorium intybus root extract can improve scalp condition in adults aged 19 years or older who require scalp moisturization due to dryness, scaling, erythema, or dandruff. The main questions it aims to answer are:
Does once-daily application of the study moisturizer improve scalp condition from baseline to week 4, as assessed by SPI-AI (Scalp Photographic Index-Artificial Intelligence)?
Read more
Does the moisturizer improve scalp biophysical parameters (erythema index, stratum corneum hydration, and transepidermal water loss) and patient-reported symptom severity over the 4-week treatment period?
Participants will:
Apply the study moisturizer once daily at bedtime to dry scalp for 4 weeks and rinse it off the following morning using their usual shampoo.
Attend study visits at baseline (week 0), week 2, and week 4 for scalp imaging, biophysical measurements, symptom questionnaires, adherence assessment, and safety monitoring.
- Conditions
- Dandruff, Seborrhoeic Dermatitis of the Scalp
- Being tested
- Ducray Kertyol P.S.O. Concentrate Cream, Ducray Laboratory, France
- Keywords
- scalp discomfort, scalp erythema, scalp dryness, scalp scaling, scalp pruritus
- Medical subject headings
- Dandruff
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ducray Kertyol P.S.O. Concentrate Cream, Ducray Laboratory, FranceOther
participants applied the moisturizer once daily to the entire scalp at bedtime
| Study group | Role | What they receive |
|---|---|---|
| Moisturizer | Active comparator | participants applies the moisturizer once daily to the entire scalp at bedtime Receives: Other: Ducray Kertyol P.S.O. Concentrate Cream, Ducray Laboratory, France |
What is being measured
The primary outcome is the main question the study is designed to answer.
SPI-AI
Scalp Photographic Index with artificial intelligence
Measured: 4week
Secondary outcomes (9)
SPI-AI
Scalp Photographic Index with artificial intelligence
Measured: 2week
Biophysical parameter
erythema index (arbitrary unit)
Measured: 2week
Biophysical parameter
erythema index (arbitrary unit)
Measured: 4week
Biophysical parameter
corneometer (arbitrary unit)
Measured: 2 week
Biophysical parameter
corneometer (arbitrary unit)
Measured: 4 week
Biophysical parameter
transepidermal water loss (g/m2/h)
Measured: 2 week
Biophysical parameter
transepidermal water loss (g/m2/h)
Measured: 4 week
Patient-reported outcome
visual analog scale (0-10) : higher is worse
Measured: 2 week
Patient-reported outcome
visual analog scale (0-10) : higher is worse
Measured: 4 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2026
- Study start1 Jul 2025
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DandruffStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 23 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seoul National University Bundang Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bo Ri Kim, Seoul National University Bundang Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07459023
- Sponsor's protocol ID
- B-2504-964-001
- Acronym
- scalp
- Status last verified
- Jan 2026
- First submitted
- 26 Feb 2026
- Last updated
- 9 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Changes in Scalp Condition After Using a Moisturizer Containing Celastrol and Cichorium Intybus Root Extract: a Prospective Clinical Trial Using Artificial Intelligence
- ClinicalTrials.gov ID
- NCT07459023
- Acronym / sponsor ID
- scalp / B-2504-964-001
- Conditions
- Dandruff, Seborrhoeic Dermatitis of the Scalp
- Keywords
- scalp discomfort, scalp erythema, scalp dryness, scalp scaling, scalp pruritus
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 23 participants (actual)
- Lead sponsor
- Seoul National University Bundang HospitalUniversity, hospital or other
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 9 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether a scalp moisturizer containing celastrol and Cichorium intybus root extract can improve scalp condition in adults aged 19 years or older who require scalp moisturization due to dryness, scaling, erythema, or dandruff. The main questions it aims to answer are:
Does once-daily application of the study moisturizer improve scalp condition from baseline to week 4, as assessed by SPI-AI (Scalp Photographic Index-Artificial Intelligence)?
Does the moisturizer improve scalp biophysical parameters (erythema index, stratum corneum hydration, and transepidermal water loss) and patient-reported symptom severity over the 4-week treatment period?
Participants will:
Apply the study moisturizer once daily at bedtime to dry scalp for 4 weeks and rinse it off the following morning using their usual shampoo.
Attend study visits at baseline (week 0), week 2, and week 4 for scalp imaging, biophysical measurements, symptom questionnaires, adherence assessment, and safety monitoring.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Moisturizer | Active comparator | Other: Ducray Kertyol P.S.O. Concentrate Cream, Ducray Laboratory, Franceparticipants applies the moisturizer once daily to the entire scalp at bedtime |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Age ≥19 years
- Presence of scalp erythema, dryness, scaling, or dandruff requiring scalp moisturization
Key exclusion criteria (3 listed)
- Active infectious scalp dermatoses
- Use of topical or systemic therapies affecting scalp status within 4 weeks prior to enrollment or during the study period
- Inability to comply with the study protocol
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ducray Kertyol P.S.O. Concentrate Cream, Ducray Laboratory, Franceparticipants applied the moisturizer once daily to the entire scalp at bedtime | Other | Moisturizer |
Primary outcome
SPI-AI
Time frame: 4week
Scalp Photographic Index with artificial intelligence
9 secondary outcomes
SPI-AI
Time frame: 2week
Biophysical parameter
Time frame: 2week
Biophysical parameter
Time frame: 4week
Biophysical parameter
Time frame: 2 week
Biophysical parameter
Time frame: 4 week
Biophysical parameter
Time frame: 2 week
Biophysical parameter
Time frame: 4 week
Patient-reported outcome
Time frame: 2 week
Patient-reported outcome
Time frame: 4 week
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Dandruff
Active, not recruitingObservational study
Itchy Scalp Biomarkers Exploration
Itchy Scalp, Pruritus
Active, not recruitingObservational study
Serum 25(OH) Vitamin D and Total Serum Immunoglobulin E Levels in Patients With Pityriasis Alba
Pityriasis Alba
Recruiting
Antidandruff Lotion Mediating Microbiome Rebalance
Dandruff
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ducray Kertyol P.S.O. Concentrate Cream, Ducray Laboratory, France in people with Dandruff and Seborrhoeic Dermatitis of the Scalp, run by Seoul National University Bundang Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SPI-AI (time frame: 4week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026; AzTrials last refreshed its copy on 28 Oct 2026.